Research programme: anti-RANKL monoclonal antibodies - Apexigen/Epitomics

Drug Profile

Research programme: anti-RANKL monoclonal antibodies - Apexigen/Epitomics

Alternative Names: APX 008

Latest Information Update: 20 Mar 2014

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen
  • Class Monoclonal antibodies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bone disorders

Most Recent Events

  • 20 Mar 2014 Preclinical development is ongoing in USA
  • 11 Dec 2012 Research programme: anti-RANKL monoclonal antibodies - Apexigen is available for licensing as of 11 Dec 2012.
  • 12 Aug 2010 Preclinical trials in Bone disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top